SEC Info - Aclaris Therapeutics, Inc. - ‘DEFA14A’ on 4/22/21

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

SCHEDULE 14A

Proxy Statement Pursuant to Section 14(a) of the
Securities Exchange Act of 1934

(Amendment No.__)

Filed by the Registrant ☒

Filed by a Party other than the Registrant ☐

Check the appropriate box:


☐	Preliminary Proxy Statement
☐	Confidential, For Use of the Commission Only (as permitted by Rule 14a-6(e)(2))
☐	Definitive Proxy Statement
☒	Definitive Additional Materials
☐	Soliciting Material Under §240.14a-12


Aclaris Therapeutics, Inc.
(Name of Registrant as Specified In Its Charter)


	(Name of Person(s) Filing Proxy Statement, if other than the Registrant)


Payment of Filing Fee (Check the appropriate box):
☒	No fee required
☐	Fee computed on table below per Exchange Act Rules 14a-6(i)(1) and 0-11.
	1)	Title of each class of securities to which transaction applies:

	2)	Aggregate number of securities to which transaction applies:

	3)	Per unit price or other underlying value of transaction computed pursuant to Exchange Act Rule 0-11 (set forth the amount on which the filing fee is calculated and state how it was determined):

	4)	Proposed maximum aggregate value of transaction:

	5)	Total fee paid:

☐	Fee paid previously with preliminary materials.
☐	Check box if any part of the fee is offset as provided by Exchange Act Rule 0-11(a)(2) and identify the filing for which the offsetting fee was paid previously. Identify the previous filing by registration statement number, or the Form or Schedule and the date of its filing.
	1)	Amount previously paid:

	2)	Form, Schedule or Registration Statement No.:

	3)	Filing Party:

	4)	Date Filed:

Your Vote Counts! ACLARIS THERAPEUTICS, INC. 2021 Annual Meeting Vote by June 2, 2021 11:59 PM ET ACLARIS THERAPEUTICS, INC. C/O BROADRIDGE P.O. BOX 1342 BRENTWOOD, NY 11717 D43768-P55024 You invested in ACLARIS THERAPEUTICS, INC. and it’s time to vote! You have the right to vote on proposals being presented at the Annual Meeting. This is an important notice regarding the availability of proxy material for the stockholder meeting to be held on June 3, 2021. Get informed before you vote View the Notice and Proxy Statement and 2020 Annual Report online OR you can receive a free paper or email copy of the material(s) by requesting prior to May 20, 2021. If you would like to request a copy of the material(s) for this and/or future stockholder meetings, you may (1) visit www.ProxyVote.com, (2) call 1-800-579-1639 or (3) send an email to sendmaterial@proxyvote.com. If sending an email, please include your control number (indicated below) in the subject line. Unless requested, you will not otherwise receive a paper or email copy. Smartphone users Point your camera here and vote without entering a control number Vote Virtually at the Meeting* June 3, 2021 9:00 AM Eastern Time Virtually at: www.virtualshareholdermeeting.com/ACRS2021 *Please check the meeting materials for any special requirements for meeting attendance. V1 For complete information and to vote, visit www.ProxyVote.com Control #

Vote at www.ProxyVote.com THIS IS NOT A VOTABLE BALLOT This is an overview of the proposals being presented at the upcoming stockholder meeting. Please follow the instructions on the reverse side to vote these important matters. Board Recommends Voting Items D43769-P55024 Prefer to receive an email instead? While voting on www.ProxyVote.com, be sure to click “Sign up for E-delivery”. 1. Election of Directors Nominees: 01) Christopher Molineaux 02) Bryan Reasons 03) Vincent Milano For 2. To approve, on an advisory basis, the compensation of our named executive officers, as disclosed in the proxy statement. For 3. To indicate, on an advisory basis, the preferred frequency of stockholder advisory votes on the compensation of our named executive officers. 1 Year 4. To ratify the selection by the Audit Committee of the Board of Directors of PricewaterhouseCoopers LLP as the independent registered public accounting firm of Aclaris Therapeutics, Inc. for its fiscal year ending December 31, 2021. For NOTE: Such other business as may properly come before the meeting or any adjournment thereof.

This ‘DEFA14A’ Filing	Date	Other Filings

	12/31/21	10-K
	6/3/21	4, 8-K, DEF 14A
	5/20/21	8-K, S-3ASR
Filed on:	4/22/21	4, DEF 14A
		List all Filings

Aclaris Therapeutics, Inc. – ‘DEFA14A’ on 4/22/21

On: Thursday, 4/22/21, at 7:03am ET · Accession #: 1558370-21-4585 · File #: 1-37581

Previous ‘DEFA14A’: ‘DEFA14A’ on 4/23/20 · Next: ‘DEFA14A’ on 4/21/22 · Latest: ‘DEFA14A’ on 4/20/23

Additional Definitive Proxy Soliciting Material — Sch. 14A — Rule 14a-12
Filing Table of Contents

This is an HTML Document rendered as filed. [ Alternative Formats ]